Histogen Announces Issuance of US Patent Covering CTS-2090 Methods of Use
The Newly Issued Patent is Expected to Provide Protection into 2040
Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases
Related news for (HSTO)
- Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering
- Histogen Announces Second Adjournment of Special Meeting of Stockholders
- Histogen Announces Second Adjournment of Special Meeting of Stockholders
- Histogen Announces Adjournment of Special Meeting of Stockholders
- Histogen Announces Board Approval of Complete Liquidation and Dissolution